TW526206B - Reshaped human antibody to human medulloblastoma cells - Google Patents

Reshaped human antibody to human medulloblastoma cells Download PDF

Info

Publication number
TW526206B
TW526206B TW083110754A TW83110754A TW526206B TW 526206 B TW526206 B TW 526206B TW 083110754 A TW083110754 A TW 083110754A TW 83110754 A TW83110754 A TW 83110754A TW 526206 B TW526206 B TW 526206B
Authority
TW
Taiwan
Prior art keywords
ser
gly
thr
sequence
gin
Prior art date
Application number
TW083110754A
Other languages
English (en)
Chinese (zh)
Inventor
Toshihiko Ohtomo
Koh Chugai Sato
Masayuki Tsuchiya
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of TW526206B publication Critical patent/TW526206B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW083110754A 1993-11-19 1994-11-18 Reshaped human antibody to human medulloblastoma cells TW526206B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29107893 1993-11-19

Publications (1)

Publication Number Publication Date
TW526206B true TW526206B (en) 2003-04-01

Family

ID=17764153

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083110754A TW526206B (en) 1993-11-19 1994-11-18 Reshaped human antibody to human medulloblastoma cells

Country Status (5)

Country Link
US (3) US6214973B1 (enExample)
EP (1) EP0729976A1 (enExample)
AU (1) AU7949394A (enExample)
TW (1) TW526206B (enExample)
WO (1) WO1995014041A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009651A1 (en) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha ANTI-INTEGRIN α3 ANTIBODY COMPLEXES
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
BR0211888A (pt) * 2001-08-13 2004-08-24 Univ Florida Res Foudantion In Materiais e métodos para promoção de reparo de tecido nervoso
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
ES2529174T3 (es) * 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20100297013A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
EA020544B1 (ru) 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
MX2016009690A (es) 2014-02-03 2017-03-03 Nat Cancer Ct Anticuerpos monoclonal anti-factor de tejido.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JPWO2019230856A1 (ja) 2018-05-31 2021-06-24 塩野義製薬株式会社 Ｎａｖ１．７モノクローナル抗体
WO2020138489A1 (ja) 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
JP7457880B2 (ja) 2021-11-01 2024-03-28 塩野義製薬株式会社 新規なＮａｖ１．７モノクローナル抗体
JPWO2023234406A1 (enExample) 2022-06-03 2023-12-07

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
EP0729976A4 (enExample) 1996-10-16
US20050249726A1 (en) 2005-11-10
EP0729976A1 (en) 1996-09-04
WO1995014041A1 (en) 1995-05-26
US6214973B1 (en) 2001-04-10
AU7949394A (en) 1995-06-06
US20030023045A1 (en) 2003-01-30
US7563599B2 (en) 2009-07-21

Similar Documents

Publication Publication Date Title
TW526206B (en) Reshaped human antibody to human medulloblastoma cells
TW458985B (en) Reconstructed human antibody against human interleukin-6
AU707440B2 (en) Antibodies against E-selectin
TW205553B (enExample)
AU2013329381B2 (en) Antibodies recognizing alpha-synuclein
ES2402521T3 (es) Reducción de las inmunogenicidades de inmunoglobulinas por corrección de la región estructural
TWI717678B (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
TW201819413A (zh) Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
JPH07504808A (ja) Ｃｄｒをグラフトしたヒト化キメラｔ細胞抗体
JP2016155803A (ja) ヒトインスリン受容体を介する医薬品の送達
JP2007106771A (ja) 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体
JPH05502384A (ja) 抗体の調製
JP2000511403A (ja) 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
JPH06502762A (ja) フレームワーク変異抗体およびそれらの調製物
CN113056486B (zh) 改善的抗flt3抗原结合蛋白
JP2022539344A (ja) 抗ｃｅａ抗体及びその応用
JP2020532279A (ja) 抗ｇｉｔｒ抗体、その抗原結合性断片、およびその医薬用途
JPH06205693A (ja) 顆粒球結合性抗体構築物、それらの製造方法および使用
CN111303283A (zh) 抗il-17a抗体及其应用
US5948647A (en) Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5849877A (en) Antigen-binding sites of antibody molecules specific for cancer antigens
JP2009504136A (ja) 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法
US5811267A (en) Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens